CY1121653T1 - C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης - Google Patents

C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης

Info

Publication number
CY1121653T1
CY1121653T1 CY20191100308T CY191100308T CY1121653T1 CY 1121653 T1 CY1121653 T1 CY 1121653T1 CY 20191100308 T CY20191100308 T CY 20191100308T CY 191100308 T CY191100308 T CY 191100308T CY 1121653 T1 CY1121653 T1 CY 1121653T1
Authority
CY
Cyprus
Prior art keywords
prevention
treatment
methods
disorders associated
esterase inhibitor
Prior art date
Application number
CY20191100308T
Other languages
English (en)
Inventor
Cynthia GALLAGHER
Stephen Ruddy
Mark Cornell MANNING
Original Assignee
Shire Viropharma Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121653(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Incorporated filed Critical Shire Viropharma Incorporated
Publication of CY1121653T1 publication Critical patent/CY1121653T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Αποκαλύπτονται συνθέσεις και μέθοδοι για την αγωγή και/ή πρόληψη διαταραχών συνδεόμενων με ανεπάρκεια αναστολέα C1 εστεράσης.
CY20191100308T 2013-03-15 2019-03-15 C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης CY1121653T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
EP14762343.3A EP2968434B1 (en) 2013-03-15 2014-03-17 C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae).

Publications (1)

Publication Number Publication Date
CY1121653T1 true CY1121653T1 (el) 2020-07-31

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100961T CY1119419T1 (el) 2013-03-15 2017-09-12 C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε)
CY20191100308T CY1121653T1 (el) 2013-03-15 2019-03-15 C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100961T CY1119419T1 (el) 2013-03-15 2017-09-12 C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε)

Country Status (30)

Country Link
US (9) US9616111B2 (el)
EP (3) EP2968434B1 (el)
JP (9) JP6184581B2 (el)
KR (4) KR102430453B1 (el)
CN (2) CN111529708A (el)
AU (3) AU2014232912A1 (el)
BR (1) BR112015023207A8 (el)
CA (2) CA2904543C (el)
CY (2) CY1119419T1 (el)
DE (1) DE202014011208U1 (el)
DK (2) DK2968434T3 (el)
EA (1) EA201591278A1 (el)
ES (2) ES2713004T3 (el)
GB (1) GB2530921B (el)
HK (2) HK1220403A1 (el)
HR (2) HRP20171269T1 (el)
HU (2) HUE041837T2 (el)
IL (2) IL241549B (el)
LT (2) LT2968434T (el)
ME (2) ME03326B (el)
MX (3) MX2020004724A (el)
NZ (2) NZ710730A (el)
PL (2) PL2968434T3 (el)
PT (2) PT3290046T (el)
RS (2) RS58351B1 (el)
SG (2) SG10201707598QA (el)
SI (2) SI3290046T1 (el)
TR (1) TR201900319T4 (el)
WO (1) WO2014145519A2 (el)
ZA (3) ZA201507604B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710730A (en) 2013-03-15 2021-07-30 Viropharma Biologics Llc C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
KR102312817B1 (ko) * 2013-11-22 2021-10-13 다케다 야쿠힌 고교 가부시키가이샤 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법
RU2017132449A (ru) * 2015-02-20 2019-03-21 Цсл Беринг Гмбх Фармацевтические композиции ингибитора c1-эстеразы
CN108025047B (zh) * 2015-05-28 2021-11-19 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
JP7189767B2 (ja) * 2015-11-19 2022-12-14 武田薬品工業株式会社 組換えヒトｃ１エステラーゼインヒビター及びその使用
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (ja) * 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
MX2019013711A (es) * 2017-05-16 2020-01-30 Octapharma Ag Preparacion de inhibidor de c1 esterasa.
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112020017626A2 (pt) 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
CN112584843A (zh) 2018-06-22 2021-03-30 顺天生化股份有限公司 用于诱发感染性免疫耐受的组合物
CA3104797A1 (en) 2018-06-22 2019-12-26 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
KR20210025062A (ko) 2018-06-22 2021-03-08 가부시키가이샤 준텐 바이오 면역 관용을 유도하는 항체, 유도된 림프구, 또한 유도된 림프구를 이용하는 세포 치료제 치료법
JPWO2021124793A1 (el) * 2019-12-16 2021-06-24
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
ES2171465T3 (es) * 1993-09-01 2002-09-16 Sanquin Bloedvoorziening Inhibidor de la esterasa de c1 para reducir lesiones de miocardio durante un infarto de miocardio agudo.
JP2000507204A (ja) 1995-12-18 2000-06-13 ステイヒテイング・サンキン・ブロードボールジーニング Ｃ１―インヒビターの補体及び血液凝固阻害特性の強化
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
DE60132169T2 (de) 2000-01-31 2008-12-11 Pharming Intellectual Property Bv Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
WO2004034971A2 (en) 2002-09-25 2004-04-29 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
PL1626736T3 (pl) 2003-05-16 2021-05-04 Pharming Intellectual Property B.V. Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
WO2007047995A2 (en) 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
ES2369522T3 (es) * 2005-12-21 2011-12-01 Pharming Intellectual Property B.V. Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión.
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
EP2109457B1 (en) 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
RU2600876C2 (ru) 2009-10-16 2016-10-27 Омерос Корпорейшен Способ лечения диссеминированного внутрисосудистого свертывания крови путем ингибирования masp-2 зависимой активации комплемента
WO2011107591A1 (en) 2010-03-05 2011-09-09 Rigshospitalet Chimeric inhibitor molecules of complement activation
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
CN104010656B (zh) 2011-09-24 2016-02-24 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
CA2858984C (en) 2011-12-22 2021-01-05 Csl Behring Gmbh Use of c1-inhibitor for the treatment of secondary edema of the central nervous system
WO2013138730A1 (en) 2012-03-16 2013-09-19 Enzon Pharmaceuticals, Inc. Polymeric conjugates of c1-inhibitors
US20160033511A1 (en) 2013-03-13 2016-02-04 Creatics Llc Methods and compositions for detecting pancreatic cancer
NZ710730A (en) * 2013-03-15 2021-07-30 Viropharma Biologics Llc C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency

Also Published As

Publication number Publication date
US20190160158A1 (en) 2019-05-30
PT2968434T (pt) 2017-09-18
IL276153A (en) 2020-09-30
JP2017105847A (ja) 2017-06-15
ZA201507604B (en) 2018-05-30
JP6877470B2 (ja) 2021-05-26
HK1250912B (zh) 2020-01-10
IL276153B (en) 2022-06-01
JP6473536B2 (ja) 2019-02-20
US11364288B2 (en) 2022-06-21
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
JP2019073545A (ja) 2019-05-16
PL2968434T3 (pl) 2018-01-31
US10080788B2 (en) 2018-09-25
CY1119419T1 (el) 2018-03-07
CA3054718A1 (en) 2014-09-18
AU2018229558B2 (en) 2020-03-05
ES2639833T3 (es) 2017-10-30
CN111529708A (zh) 2020-08-14
DK2968434T3 (en) 2017-09-11
KR102579789B1 (ko) 2023-09-15
EP3508213A1 (en) 2019-07-10
PL3290046T3 (pl) 2019-05-31
MX2020004724A (es) 2022-01-18
JP2019073546A (ja) 2019-05-16
LT3290046T (lt) 2019-03-12
KR20220070049A (ko) 2022-05-27
EP2968434B1 (en) 2017-06-28
EP3290046B1 (en) 2019-01-02
KR102430453B1 (ko) 2022-08-05
JP2018119002A (ja) 2018-08-02
RS58351B1 (sr) 2019-03-29
EA201591278A1 (ru) 2016-03-31
US20160015795A1 (en) 2016-01-21
JP6473534B2 (ja) 2019-02-20
CA2904543A1 (en) 2014-09-18
JP2019073544A (ja) 2019-05-16
BR112015023207A2 (pt) 2017-11-21
ZA201706929B (en) 2019-05-29
HUE041837T2 (hu) 2019-05-28
GB2530921B (en) 2017-09-20
TR201900319T4 (tr) 2019-02-21
ME03326B (me) 2019-10-20
LT2968434T (lt) 2017-09-25
HRP20171269T1 (hr) 2017-11-03
ME02865B (me) 2018-04-20
JP2021088599A (ja) 2021-06-10
HUE036224T2 (hu) 2018-06-28
PT3290046T (pt) 2019-02-18
JP2016516073A (ja) 2016-06-02
AU2014232912A1 (en) 2015-09-03
NZ751555A (en) 2021-07-30
US20180110844A1 (en) 2018-04-26
SI3290046T1 (sl) 2019-04-30
MX2021011946A (es) 2021-11-17
WO2014145519A2 (en) 2014-09-18
KR20210129267A (ko) 2021-10-27
US20170224788A1 (en) 2017-08-10
HRP20190270T1 (hr) 2019-04-05
US10105423B2 (en) 2018-10-23
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
MX2015011281A (es) 2016-03-03
AU2020203183B2 (en) 2022-06-02
GB201519921D0 (en) 2015-12-23
SG10201707598QA (en) 2017-10-30
DK3290046T3 (en) 2019-03-18
SG11201507616VA (en) 2015-10-29
AU2018229558A1 (en) 2018-10-04
SI2968434T1 (sl) 2017-11-30
JP6473535B2 (ja) 2019-02-20
US20190160157A1 (en) 2019-05-30
US20180153972A1 (en) 2018-06-07
CA2904543C (en) 2019-10-08
JP6877472B2 (ja) 2021-05-26
AU2020203183A1 (en) 2020-06-04
CN105517559A (zh) 2016-04-20
IL241549B (en) 2020-08-31
US9616111B2 (en) 2017-04-11
JP6877471B2 (ja) 2021-05-26
ES2713004T3 (es) 2019-05-17
JP6184581B2 (ja) 2017-08-23
JP6422520B2 (ja) 2018-11-14
EP2968434A2 (en) 2016-01-20
US20180085441A1 (en) 2018-03-29
KR20210021146A (ko) 2021-02-24
US11534482B2 (en) 2022-12-27
WO2014145519A3 (en) 2014-12-31
KR20150135242A (ko) 2015-12-02
HK1220403A1 (zh) 2017-05-05
GB2530921A (en) 2016-04-06
US20200261556A1 (en) 2020-08-20
EP3290046A1 (en) 2018-03-07
BR112015023207A8 (pt) 2018-01-23
ZA201806793B (en) 2020-01-29
JP2018119000A (ja) 2018-08-02
EP2968434A4 (en) 2016-03-02
DE202014011208U1 (de) 2018-08-23
JP2018119001A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
CY1122631T1 (el) Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MD3307288T2 (ro) Compoziții care conțin tulpini bacteriene
MD3360558T2 (ro) Compoziții care cuprind tulpini bacteriene
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
MD3204024T2 (ro) Compoziții care conțin tulpini bacteriene
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
TR201907044T4 (tr) Yeni bileşikler.
BR112018007290A2 (pt) minha patente 1